Procaps Group S.A.

PROC

LU2376511205

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-16 pm EDT			5-day change	1st Jan Change
2.58 ^USD	-0.39%		-6.52%	-36.61%

May. 01	Procaps Group S.A. Provides Earnings Guidance for the Year Ended December 31, 2023	CI
Mar. 04	Procaps Group S.A. Announces Formation of Strategic Committee to Explore Value Creation Alternatives	CI

Procaps Group S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023

June 06, 2023 at 06:09 am EDT

Procaps Group S.A. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 84.16 million compared to USD 85.63 million a year ago. Net income was USD 6.62 million compared to USD 16.45 million a year ago.

Basic earnings per share from continuing operations was USD 0.07 compared to USD 0.16 a year ago.

Latest news about Procaps Group S.A.

Procaps Group S.A. Provides Earnings Guidance for the Year Ended December 31, 2023	May. 01	CI
Procaps Group S.A. Announces Formation of Strategic Committee to Explore Value Creation Alternatives	Mar. 04	CI
Procaps Group Announces Formation of Strategic Committee to Explore Value Creation Alternatives	Mar. 03	CI
Hoche Partners Pharma Holding S A Issues a Letter to Procaps Group, S A	Feb. 20	CI
Declaration of Voting Results by Procaps Group, S A	Jan. 24	CI
Hoche Partners Sends a Letter to Procaps Group	Jan. 12	CI
Procaps Group S.A. Provides Earnings Guidance for the Full Year 2023	Dec. 26	CI
Procaps Group S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Dec. 26	CI
Tranche Update on Procaps Group S.A.'s Equity Buyback Plan announced on June 1, 2023.	Dec. 26	CI
Procaps Group Teams Up With Genomma Lab to Manufacture, Market Softgel Products in Latin America	Nov. 30	MT
Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America	Nov. 29	CI
Procaps Group Names Jose Antonio Vieira as CEO	Nov. 22	MT
Procaps Group S.A. Announces Executive Changes, Effective January 15, 2024	Nov. 22	CI
Procaps Group S.A. Appoints Sandra Sanchez Y Oldenhage as A Director	23-10-23	CI
Transcript : Procaps Group S.A. - Special Call	23-10-10
Procaps Group S.A.(NasdaqGM:PROC) dropped from S&P Global BMI Index	23-09-18	CI
Procaps Group, S.A. Announces the Expansion of Its Oncology Portfolio	23-09-07	CI
Brookline Capital Downgrades Procaps to Hold From Buy, Price Target is $4.50	23-09-06	MT
Transcript : Procaps Group S.A., Q2 2023 Earnings Call, Sep 05, 2023	23-09-05
Earnings Flash (PROC) PROCAPS GROUP S.A. Posts Q2 Revenue $110M	23-09-05	MT
Procaps Group S.A. Announces Resignation of Mr. Alejandro Weinstein from the Board of Directors	23-09-05	CI
Procaps Group S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-05	CI
Procaps Group S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-06	CI
Procaps Group Q1 Earnings, Revenue Decline	23-06-06	MT
Procaps Group S.A. commences an Equity Buyback Plan for 11,282,418 shares, representing 10% of its issued share capital, under the plan approved on June 28, 2022.	23-05-31	CI

Chart Procaps Group S.A.

Duration

Period

More charts

Company Profile

Procaps Group SA is a Luxembourg-based healthcare and pharmaceutical company. The Company develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. It operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Procaps Group S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.58 USD

Average target price

4.75 USD

Spread / Average Target

+84.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PROCAPS GROUP S.A.	-36.61%	292M
ELI LILLY AND COMPANY	+32.36%	709B
NOVO NORDISK A/S	+30.77%	595B
JOHNSON & JOHNSON	-1.60%	367B
MERCK & CO., INC.	+20.07%	334B
ABBVIE INC.	+6.04%	289B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	211B
ROCHE HOLDING AG	-3.97%	203B
AMGEN INC.	+9.27%	171B

Other Pharmaceuticals

Procaps Group S.A.

Equities

PROC

LU2376511205

Pharmaceuticals

Procaps Group S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023

Latest news about Procaps Group S.A.

Chart Procaps Group S.A.

Company Profile

Income Statement Evolution

Ratings for Procaps Group S.A.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals